- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | SpyGlass Pharma Q2 GAAP EPS of -$0.59 | 1 | Seeking Alpha | ||
| Do | SpyGlass Pharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Do | SpyGlass Pharma, Inc. Loss At -$19.864 Mln In Q2 | 2 | RTTNews | ||
| 15.06. | SpyGlass Pharma, Inc.: SpyGlass Pharma Appoints Shannon Treviño as General Counsel | 3 | GlobeNewswire (USA) | ||
| 02.06. | SpyGlass Pharma ernennt Mike Pinder zum neuen Marketing-Vizepräsidenten | 2 | Investing.com Deutsch | ||
| SPYGLASS PHARMA Aktie jetzt für 0€ handeln | |||||
| 02.06. | SpyGlass Pharma appoints Mike Pinder as VP of marketing | 1 | Investing.com | ||
| 15.05. | SpyGlass Pharma, Inc. GAAP EPS of -$0.69 | 1 | Seeking Alpha | ||
| 14.05. | SpyGlass Pharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 27.03. | SpyGlass Pharma: Stifel bekräftigt "Kaufen"-Rating und Kursziel von 42 Dollar | 1 | Investing.com Deutsch | ||
| 27.03. | Stifel reiterates Buy on SpyGlass Pharma stock, $42 target | 1 | Investing.com | ||
| 26.03. | SpyGlass Pharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | SpyGlass Pharma, Inc. GAAP EPS of -$5.72 | 1 | Seeking Alpha | ||
| 26.03. | SpyGlass Pharma, Inc.: SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update | 232 | GlobeNewswire (Europe) | Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost... ► Artikel lesen | |
| 26.03. | SpyGlass Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating | 5 | Investing.com | ||
| 09.03. | SpyGlass Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.03. | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 568 | GlobeNewswire (Europe) | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| 03.03. | Leerink initiates SpyGlass Pharma stock with Outperform rating | 1 | Investing.com | ||
| 03.03. | Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential | 1 | Investing.com | ||
| 09.02. | SpyGlass Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,390 | 0,00 % | If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,770 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 361,08 | +0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 26,250 | 0,00 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,040 | -0,11 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,290 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| AMYLYX PHARMACEUTICALS | 22,820 | 0,00 % | Amylyx anticipates Phase III LUCIDITY top-line data in late August or early September with $250.8M cash runway into 2028 | ||
| DISC MEDICINE | 77,44 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 43,490 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,79 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 53,14 | 0,00 % | Citizens lowers Structure Therapeutics stock price target on GLP agonist | ||
| VERA THERAPEUTICS | 32,850 | -0,12 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen SPYGLASS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 25,310 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYGLASS PHARMA INC finden Sie auf Wallstreet Online.